Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. PAAB Q&A
  3. Unbranded disease info + Guidelines (therapeutic categories)
PAAB Notice
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

Unbranded disease info + Guidelines (therapeutic categories)

Scheduled Pinned Locked Moved PAAB Q&A
2 Posts 2 Posters 291 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • NatBourreN Offline
    NatBourreN Offline
    NatBourre
    wrote on last edited by
    #1

    Content was created independently by a group of Canadian physicians where they provide information on how to differentiate between several disease states that closely resemble one another. They also included information from the consensus guidelines, which mentions all the therapeutic categories equally (no emphasis on any category, simply lists 1st line therapeutic category, 2nd line category, 3rd line category. My client was the sponsor for this project but the tool will remain unbranded (no product logo, no brand colours). Their sales reps will not be distributing the tool. A 3rd party will distribute the tool to Canadian physicians. Does this need to be reviewed by PAAB?

    Natalie Bourré
    Marketing 4 Health Inc.
    Medical Marketing Consultant, Medical Writer
    nat@marketing4health.net

    Jennifer CarrollJ 1 Reply Last reply
    0
    • NatBourreN NatBourre

      Content was created independently by a group of Canadian physicians where they provide information on how to differentiate between several disease states that closely resemble one another. They also included information from the consensus guidelines, which mentions all the therapeutic categories equally (no emphasis on any category, simply lists 1st line therapeutic category, 2nd line category, 3rd line category. My client was the sponsor for this project but the tool will remain unbranded (no product logo, no brand colours). Their sales reps will not be distributing the tool. A 3rd party will distribute the tool to Canadian physicians. Does this need to be reviewed by PAAB?

      Jennifer CarrollJ Offline
      Jennifer CarrollJ Offline
      Jennifer Carroll
      wrote on last edited by
      #2

      Good Morning @natbourre

      Please see Q&A 634, particularly the PAAB Advisory Guidance on which HCP materials require PAAB review, which contains a decision tree to describe the key elements in the assessment. To make an assessment, we would require further elaboration on the content, nature of the sponsorship and selection of the author group. We would also require elaboration on the “3rd party distribution”. If the sponsor has influence on choosing the topic and/or plays a role in the distribution by the 3rd party, we would recommend submitting for an opinion. The opinion would be to assess the influence of the sponsorship (as noted in the above guidance, examples of “influence” include control or input on the specific topic, content, author selection, audience, frequency, etc.) and the overall message of the piece. The standard litmus test is “could a reader identify the sponsor” and “would a competitor be equally as likely to promote this tool”.

      1 Reply Last reply
      0
      Reply
      • Reply as topic
      Log in to reply
      • Oldest to Newest
      • Newest to Oldest
      • Most Votes


      • Login

      • Don't have an account? Register

      • Login or register to search.
      • First post
        Last post
      0
      • Categories
      • Recent
      • Tags
      • Popular
      • Users
      • Groups